A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders
V E Medvedev, O N Tereshchenko, A Iu Israelian, I K Chobanu, N V Kost, O Iu Sokolov, N F Miasoedov · 2014 · Zh Nevrol Psikhiatr Im S S Korsakova. 114(7):17–22
What does this source report?
An active-comparator report describes anxiety and quality-of-life changes.
- Population and setting
- 60 patients with anxiety/phobic or somatoform disorders
- Evidence type
- Human comparative study
- Preparation
- Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted
- Source language
- See original publication; indexed English metadata
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Random allocation and blinding are not established from the abstract.
- Short follow-up and a small comparison cannot establish long-term safety or general cognitive enhancement.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: V E Medvedev, O N Tereshchenko, A Iu Israelian, I K Chobanu, N V Kost, O Iu Sokolov, N F Miasoedov. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders Zh Nevrol Psikhiatr Im S S Korsakova. 114(7):17–22 2014.
Molekul research summary: https://molekul.io/research/ss-25176261. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry